- In a comparison of filter deposition of salbutamol administered to
wheezy infants aged 4 to 12 months with either a nebulizer (Pari-Baby)
or MDI/spacer (Nebuchamber or detergent-coated Babyhaler), the mean
deposition was only 25.3% of the total nebulized dose, but was 40.2%
and 40.7% for the MDI/spacers.3
- In 15 infants and toddlers (age range 3 months to 5 years), technetium-labeled
salbutamol was administered by MDI and spacer (non-detergent treated
Aerochamber). Most of the actuated dose remained in the spacer, with
a distribution of 1.97 +/-1.4% in the lungs, 1.28 +/-0.77% in the oropharynx,
and 1.11 +/-2.4% in the stomach. This was compared with two adult controls
with 19% in the lungs and 2% in the stomach.4
- In 8 children between the ages of 1 and 4 years, technetium-labeled
salbutamol was administered by MDI and spacer (detergent-treated Babyhaler).
Mean deposition of the actuated dose was 16.4% +/-5.5% in the lungs,
20.9% +/- 5.1% in the GI system (mouth, throat, esophagus, and stomach).
For comparison, 5 children aged 8 to 12 years had lung deposition of
41.8% +/- 3.8% and GI deposition of 16.5% +/- 3.0%.2
HM, Devadason SG, Hop WCJ, LeSouef PN, De Jongste JC, Tiddens HAWM.
Variability of aerosol delivery via spacer devices in young asthmatic
children in daily life. Eur Respir J 1999; 13:787-791.
JH, Janssens HM, Pierart F, Dore ND, Devadason SG, and LeSouef PN. High-percentage
lung delivery in children from detergent-treated spacers. Pediatric
Pulmonology 2000; 29:389-393.
JH, Devadason SG, Hayden MJ, Eber E, Summers QA, LeSouef PN. Aerosol
delivery to wheezy infants: A comparison between a nebulizer and two
small volume spacers. Pediatric Pulmonology 1997; 23:212-216.
A, Golan H, Grauer N, Aviram M, Albin D, Quastrel MR. Deposition pattern
of radiolabeled salbutamol inhaled from a metered-dose inhaler by means
of a spacer with mask in young children with airway obstruction. J
Pediatr 1996; 128:479-484.